Transcatheter Device Closure of Muscular Ventricular Septal Defect
Traditional treatment of muscular ventricular septal defect (VSD) is surgical closure, but it carries considerable morbidity and mortality. The Amplatzer muscular VSD occluder (AGA Medical Corporation, Plymouth, MN, USA) was approved by the United States Food and Drug Administration in September 200...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2011-02-01
|
| Series: | Pediatrics and Neonatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957210000203 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849728050896306176 |
|---|---|
| author | Yun-Ching Fu |
| author_facet | Yun-Ching Fu |
| author_sort | Yun-Ching Fu |
| collection | DOAJ |
| description | Traditional treatment of muscular ventricular septal defect (VSD) is surgical closure, but it carries considerable morbidity and mortality. The Amplatzer muscular VSD occluder (AGA Medical Corporation, Plymouth, MN, USA) was approved by the United States Food and Drug Administration in September 2007 and by the Taiwan Department of Health in September 2009. It is a self-expandable double-disc device made from a nitinol wire mesh. Dacron polyester patches are sewn into each disc and the connecting waist to increase the thrombogenicity of the device. Many reports have shown that transcatheter device closure of muscular VSDs is effective and safe. It has no scar, less pain, shorter hospital stay, and less cost compared to the traditional open heart surgery. |
| format | Article |
| id | doaj-art-89f6b99856b5443fb3c436e63fef01a4 |
| institution | DOAJ |
| issn | 1875-9572 |
| language | English |
| publishDate | 2011-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pediatrics and Neonatology |
| spelling | doaj-art-89f6b99856b5443fb3c436e63fef01a42025-08-20T03:09:41ZengElsevierPediatrics and Neonatology1875-95722011-02-015213410.1016/j.pedneo.2010.12.012Transcatheter Device Closure of Muscular Ventricular Septal DefectYun-Ching Fu0Department of Pediatrics, Lin-Shin Hospital, Taichung, TaiwanTraditional treatment of muscular ventricular septal defect (VSD) is surgical closure, but it carries considerable morbidity and mortality. The Amplatzer muscular VSD occluder (AGA Medical Corporation, Plymouth, MN, USA) was approved by the United States Food and Drug Administration in September 2007 and by the Taiwan Department of Health in September 2009. It is a self-expandable double-disc device made from a nitinol wire mesh. Dacron polyester patches are sewn into each disc and the connecting waist to increase the thrombogenicity of the device. Many reports have shown that transcatheter device closure of muscular VSDs is effective and safe. It has no scar, less pain, shorter hospital stay, and less cost compared to the traditional open heart surgery.http://www.sciencedirect.com/science/article/pii/S1875957210000203heart catheterizationheart defectsventricular septal defect |
| spellingShingle | Yun-Ching Fu Transcatheter Device Closure of Muscular Ventricular Septal Defect Pediatrics and Neonatology heart catheterization heart defects ventricular septal defect |
| title | Transcatheter Device Closure of Muscular Ventricular Septal Defect |
| title_full | Transcatheter Device Closure of Muscular Ventricular Septal Defect |
| title_fullStr | Transcatheter Device Closure of Muscular Ventricular Septal Defect |
| title_full_unstemmed | Transcatheter Device Closure of Muscular Ventricular Septal Defect |
| title_short | Transcatheter Device Closure of Muscular Ventricular Septal Defect |
| title_sort | transcatheter device closure of muscular ventricular septal defect |
| topic | heart catheterization heart defects ventricular septal defect |
| url | http://www.sciencedirect.com/science/article/pii/S1875957210000203 |
| work_keys_str_mv | AT yunchingfu transcatheterdeviceclosureofmuscularventricularseptaldefect |